Summary
Biogen Inc. (BIIB) has filed an 8-K report on July 31, 2025, to announce its financial results for the second quarter ended June 30, 2025. The key details of these results are contained within a press release furnished as Exhibit 99.1 to the filing. Investors should refer to this press release for specific financial performance metrics, including revenue, profitability, and any significant operational updates impacting the company's financial condition. This filing is made under Item 2.02, which means the press release is furnished and not deemed 'filed' for certain regulatory purposes. While it provides crucial information for understanding Biogen's recent performance, it's important to note that this disclosure does not alter the company's legal obligations under the Securities Exchange Act of 1934 or the Securities Act of 1933. Investors should consult the press release directly for comprehensive insights into the second quarter's financial outcomes and any forward-looking statements the company may have made.
Key Highlights
- 1Biogen Inc. announced second quarter 2025 financial results on July 31, 2025.
- 2Details of the financial results are provided in a press release furnished as Exhibit 99.1.
- 3The filing is an 8-K Current Report, indicating a significant event or update.
- 4Investors should review the press release for specific performance data for the quarter ended June 30, 2025.
- 5The furnished press release contains information on operations and financial condition.
- 6This disclosure is made under Item 2.02 of Form 8-K.